Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

49.03 +0.40 (+0.82%)
Streaming Delayed Price Updated: 11:36 AM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
News headline image
Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy ↗
Sanofi revealed topline data from the ElevAATe phase 2 study of efdoralprin alfa (SAR447537, formerly known as INBRX-101). 
Via Benzinga
News headline image
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the... 
Via MarketMinute
News headline image
Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease ↗
CHMP rejects Sanofi's Rezurock for chronic GVHD in the EU, while approving Wayrilz for ITP, highlighting mixed outcomes for new treatments. 
Via Benzinga
Why Immuneering Stock Soared Over 40% After-Hours Today ↗
Via Stocktwits
News headline image
Is Sanofi Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times ↗
The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions. 
Via Benzinga
News headline image
Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program ↗
The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks. 
Via Stocktwits
News headline image
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential ↗
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least $5 billion. 
Via Benzinga
News headline image
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out ↗
The small biotech company is looking to take on Regeneron and Sanofi's blockbuster, Dupixent. 
Via Investor's Business Daily
News headline image
Sanofi AlphaMedix Study Hits Key Milestones In Phase 2 Study ↗
Sanofi reports that its AlphaMedix phase 2 trial showed strong efficacy and survival benefits in gastroenteropancreatic neuroendocrine tumors. 
Via Benzinga
News headline image
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September ↗
Results of the Resolve-AD trial with rezpegaldesleukin were better than expected. 
Via The Motley Fool
News headline image
AI Revolutionizes Pharma: Market Soars Towards $65 Billion by 2033, Promising a New Era of Medicine
The pharmaceutical industry is on the cusp of a profound transformation, driven by the accelerating integration of Artificial Intelligence (AI). Projections indicate that the global AI in... 
Via TokenRing AI
Topics Artificial Intelligence Economy
News headline image
Thermo Fisher Scientific Soars on Strategic Wins, Market Optimism
Thermo Fisher Scientific Inc. (NYSE: TMO) experienced a robust surge in its stock value today, October 1, 2025, climbing an impressive 9.79% as market optimism swelled around a series of recent... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Novavax Amends Deal With Sanofi, Broadens Partnership ↗
The amendment of the agreement allows for the use of Matrix-M in early-stage development of Sanofi's pandemic influenza vaccine candidate. 
Via Stocktwits
News headline image
GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley ↗
Shares had broke out earlier this month, but have floundered at the lower boundary of the chart pattern. 
Via Investor's Business Daily
News headline image
Immuneering Corporation's Stock Takes a Hit Amidst Funding Round Despite Promising Clinical Data
Boston, MA – September 27, 2025 – Immuneering Corporation (NASDAQ: IMRX) experienced a significant downturn in its stock value on September 25, 2025, with shares declining by approximately 13.3%. This... 
Via MarketMinute
News headline image
Amgen Expands US Manufacturing Network Amid New Tariff Policy ↗
Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 million expansion of its U.S. manufacturing network. 
Via Benzinga
Topics Government World Trade
News headline image
Sanofi Expands Insulin Savings Program To Cover All US Patients ↗
The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA’s (NASDAQ:... 
Via Benzinga
News headline image
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
News headline image
Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now ↗
BigBear.ai is bigger than both of these AI-focused companies now. That could change. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
FDA Delays Key Sanofi Multiple Sclerosis Drug Decision ↗
Sanofi's tolebrutinib review for non-relapsing multiple sclerosis has been extended by the FDA until December 2025. 
Via Benzinga
News headline image
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Sanofi Reports Early Brivekimig Data, Signals Strong Efficacy And Good Tolerability ↗
Sanofi reports show significant improvements in hidradenitis suppurativa symptoms, with higher response rates and reduced lesions. 
Via Benzinga
News headline image
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit ↗
AstraZeneca pauses its £200 million UK investment as rising costs, undervaluation, and unclear policies hinder pharma R&D and foreign capital inflows. 
Via Benzinga
Topics Government
News headline image
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again ↗
The company is working on a treatment for an autoimmune disease that affects the muscles. 
Via Investor's Business Daily
News headline image
Roblox To Rally Around 34%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
This Veeva Systems Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
Why Nektar Therapeutics Rippled Higher This Week ↗
The company's competitive positioning might be stronger now, after disappointing results from a key rival. 
Via The Motley Fool
Topics Intellectual Property
News headline image
What's Going On With Nektar Therapeutics Stock On Thursday? ↗
Nektar Therapeutics stock is trading higher with no news, possibly due to Sanofi's disappointing results. 
Via Benzinga
News headline image
Why Is Sanofi Stock Falling Thursday? ↗
William Blair notes OX40 antibodies rocatinlimab and amlitelimab trail Dupixent in efficacy, with dosing and side effects shaping their market potential. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.